COVID-19 has brought unprecedented challenges to quality and supply chain management within the life sciences industry. Drug shortages caused by unprecedented supply and demand pressures continue to be significant challenges for many life sciences companies today and for the general public at large as the pandemic continues to escalate.
The Fragile State of the Pharmaceutical Supply Chains in the US
According to a recent report by the Center for Infectious Disease Research and Policy (CIDRAP), the US domestic pharmaceutical supply chain remains in a state of heightened vulnerability, with almost three quarters of the critical drugs required to treat COVID-19 patients facing significant shortages. The current shortages have brought quality management into the spotlight for many life science organizations and have tightened the focus on issues of quality maturity across the larger pharmaceutical manufacturing value chain.
Beyond supply chain disruption, additional factors including implementation of new public health safety protocols, … Read more...